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We earlier reviewed how obesity has assumed an endemic/pandemic 
proportions that has resulted in escalating incidence and prevalence of 
associated escalating worldwide incidence of Metabolic Syndrome (MetS) 
with non alcoholic fatty liver disease (NAFLD), that is correlated with 
enhanced morbidity. Later we tried to detail how probiotics, L-Carnitine 
(LC), Nicotinamide Ribose (NR) Combination, along with Apical Sodium 
Dependent Bile Acids Transporter (ASBT) or Volixibat and Silybin, 
Vitamin D, Allyl Isothiocyanate (AITC), might aid in treating and 
understand the etiopathogenesis of NAFLD. The prevalence of NAFLD 
all over the world is approximately 25%, with that of non alcoholic 
steatohepapititis (NASH), varying from 1.5%=6.45%. Particularly NASH, 
specifically the ones associated with fibrosis possess a greater chance of 
generation of side effects that include progression to cirrhosis as well as 
liver-associated mortality. Despite an improvement was observed with 
vitamin E, Pioglitazone. liraglutide in histological appearance in liver 
randomized controlled clinical trials (RCT), at present no drugs exists 
that have received FDI approval for NASH. The aim of this review was 
to update the newer drugs getting evaluated, undergoing phase 2-3 trials. 
Currently there are Obeticholic acid, elafibranor, cenicriviroc, resmetriom, 
in addition to aramchol, that are the five agents that are getting analysed 
in big, histology dependent phase 3 trials. Hopefully within another 2-4 
years, newer, efficacious drugs will be available for the therapy of NASH. 
Besides that a lot of phase 2 trials are continuing for different drugs. 
Further depending on outcomes of phase 2-3 trials, combination treatments 
are getting evaluated. For future therapeutic approaches would be made 
up of variations in NASH phenotypes, besides personalized approaches 
based on various NASH phenotypes in addition to response of every single 
patient. Further recently there were reports of utilization of curcumin with 
nonselective beta blocker for regression from cirrhosis (reviewed by us). 
Hopefully once there are approved therapies for NAFLD/NASH, we can 
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1. Introduction
Earlier we have reviewed how obesity is assuming an 
endemic/pandemic proportions resulting in escalating 
incidence as well as Prevalence associated escalating 
worldwide incidence of Metabolic Syndrome (MetS) with 
Non alcoholic fatty liver disease (NAFLD) [1-9], that is 
correlated with enhanced morbidity [8]. We tried to detail 
how probiotics, L-Carnitine (LC), Nicotinamide Ribose 
(NR) Combination, along with Apical Sodium Dependent 
Bile Acids Transporter (ASBT) or Volixibat and Silybin, 
Vitamin D, Allyl Isothiocyanate (AITC), SGLT Inhibitors 
etc might aid in treating and understand the etiopathogen-
esis of NAFLD. By definition non alcoholic fatty liver 
disease(NAFLD), classificationcan be performed histo-
logically into non alcoholic fatty liver or non alcoholic 
steatohepapititis (NASH). The prevalence all over the 
world is escalating, being approximately 25%, with that of 
NASH varying from 1.5%-6.45% [10]. The cases of NASH 
particularly the ones with fibrosis posseses greater chanc-
es of side effects like cirrhosis as well as fibrosis–associ-
ated mortality [11-13]. The maximum significant histological 
parameter of NAFLD correlated with long time mortality 
is fibrosis (stage 2-4) [12,14]. Hence of these 2 surrogate 
endpoints require to get validated in phase 2b or 3 trials 
for the conditional passing of the drug for generation: i) 
rectification of NASH without deterioration of fibrosis 
or; ii) fibrosis getting decreased by 1 or > stages without 
deterioration of NASH [15]. Despite no FDA approved 
drugs for NASH, vitamin E, Pioglitazone, along with Li-
raglutide escalated liver histology of patients with NASH 
in randomized controlled clinical trial [16-18]. In spite of 
Vitamin E possessing potential advantages, it has been 
correlated with contradictory outcomes of total mortality 
[19], the haemorrhagic stroke [20] as well as prostate cancer 
in males >than 50 years age [21]. Pioglitazone results in 
weight escalation [16], with its utility in NASH still getting 
evaluated although now Sodium–glucose cotransporter 2 
(SGLT2) inhibitors are being evaluated in view of lack of 
above limitation, hence adversities need to get balanced 
with the potential advantages in NASH patients [reviewed 
by us], having no other option for therapy besides lifestyle 
changes. Currently weight reduction as well as lifestyle 
changes with the utilization of diet as well as exercise 
is advocated as the 1st line treatment [22,23]. Nevertheless, 
long time compliance with lifestyle changes is tough for 
sustenance in target population. Thus, a main requirement 
that has not been resolved for a new agent is to resolve 
NASH along with reversal of liver fibrosis are present. 
The current major targets for NASH treatment are these: 
i) bile acid pathway, insulin resistance (IR), inflammation, 
Thyroid hormone receptor (THR)-β stimulation, hepatic 
lipid metabolism, antifibrosis etc. 5 Pharmacologic drugs: 
i)Obeticholic acid (OCA; Farsenoid X receptor [FXR] ag-
onist); ii) Elafibranor (a Peroxisome Proliferator Activated 
Receptor [PPAR] α as well as δ agonist); iii) cenicrivi-
roc (CVC-a dual antagonist of C-C chemokine receptor 
(cenicriviroc CCR) types 2 as well as 5; iv) resmetriom 
(THR-β- agonist) as well as aramchol (stearoyl-Co A de-
saturase [SCD1 inhibitor-resulted in enhancement of liver 
histology in phase 2 studies [24-28] along with are going 
through evaluation of their long term effectiveness as well 
as safety. In addition a lot of innovative agents that target 
NASH-associated pathways that are undergoing phase 1 
as well as 2 trials are about 200 in number. Pharmacolog-
ic drugs are being analysed for NASH therapy. Here we 
review the mode of action of maximum Pharmacologic 
drugs that are significant as well as describe the key phase 2 
as well as 3 studies which got finished or are still ongoing.
2. Classification of the Agents Dependent on 
the Mode of Action
2.1 AObeticholic Acid (OCA; Farsenoid X receptor 
[FXR] agonist)
OCA is obtained from the primary human bile acid, 
chenodeoxycholic acid, that is a natural Farsenoid X recep-
tor [FXR] agonist [29]. FXR is a nuclear receptor which gets 
significantly expressed in the liver along with small intestine, 
having a significant part in the generation in addition to en-
terohepatic circulation of bile acids (Figure 1) [30,31]. Stimu-
lation of FXR decreases bile acids generation by hampering 
the transformation of cholesterol to bile acids, as well as it 
has anti-inflammatory along with anti-fibrogenic action [32]. 
Stimulation of FXR in the ileum further hampers the up-
take of bile acids by resulting in downregulation of Sodium 
dependent bile acid transporter. Lastly, OCA influences an-
ticholestatic as well as hepatoshielding action by controlling 
the metabolism of cholesterol as well as bile acids [33].
In a phase 2a Clinical trial over OCA, patients with 
type 2 Diabetes mellitus (DM) as well as NAFLD were 
randomly divided to groups receiving 25 mg OCA (n=20), 
or groups receiving 50 mg OCA (n=21) or groups receiv-
ing placebo (n=23) once/day for 6 weeks (NCT00501592) 
[34]. Enhancement of insulin sensitivity occurred by 24.5 
(p=0.011) in the combined OCA groups, while a reduc-
tion by 5.5% occurred in the placebo group. Significant 
decrease in the amounts of γ glutamyl transferase (γGT) 
as well as alanine amino transferase (ALT). Further oc-
curred in the OCA groups, besides dose-associated weight 
reduction. Further, a significant reduction in the amounts 
of liver fibrosis markers were observed in the OCA groups 
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receiving 25 mg. In a phase 2b clinical trial, noncirrhotic 
patients with NASH had a random division into 1:1 to 
groups receiving placebo (n=142) as well as 25 mg OCA 
(n=141) once/day for 72 weeks (FLINT NCT012605498) 
[24]. Fifty (45%) of the 110 patients in the OCA groups 
displayed enhancement of liver histology in contrast to 23 
(21%) of 109 patients in the placebo group (RR,1.9; 95% 
Confidence interval [CI], 1.3-2.8P=0.0002). Further 2.3% 
of the OCA groups had pruritus occurring in contrast to 6% 
the placebo group. Enhancement of histological param-
eters of NASH, nevertheless, its long time advantage as 
well as safety requires more elaboration.
During the interim evaluation of an ongoing, phase 3 
study of OCA, patients with NASH, an NAFLD activity 
score (NAS) of a minimum of 4, as well as fibrosis stage 
F2-F3, or F1 with a minimum of one associated comor-
bidity got randomly divided to into 1:1:1 ratio for get-
ting placebo, OCA 10 mg or OCA 25 mg (GENERATE, 
NCT02548351) [35]. The primary evaluation implicated 
931 patients with stage F2-F3 fibrosis (311 in the placebo 
group, 312 in the OCA 10 mg group as well as 308 in the 
OCA 25 mg group). The fibrosis escalation endpoint was 
attained by 37 (12%) patients in the placebo group, 55 
(18%) in the OCA 10 mg group (p=0.045), as well as 71 
(23%) in the OCA 25 mg (P=0.0002). The resolution point 
in NASH was not reached. Nevertheless, the outcomes 
of this interim evaluation demonstrated that, OCA 25 mg 
resulted in significant ameliorated fibrosis along with cru-
cial constituents of NASH action.
The safety population (1968 patients with fibrosis stage 
F2-F3) belonging to this trial, the commonest side effect 
was pruritus, that took place in 5% of the OCA 25 mg 
group, 28% of the OCA 10 mg group, as well as 19% of 
placebo group. Mostly pruritus was of mild moderate de-
gree. Nevertheless, 9% of OCA 25 mg safety population 
omitted the drug secondary to pruritus. The lipoprotein 
profile was further watched in the safety population. The 
average low density lipoprotein (LDL) cholesterol as well 
as total cholesterol amount reached maximum amounts 
at 3 months in the OCA group. Further 17% of the OCA 
group as well as 7% of the placebo group required statin 
therapy.
A phase 2 trial (CONTROL, NCT02633956) that tried 
to analyse the utilization of OCA in combination of statin 
therapy for NASH demonstrated that utilization of OCA 
at 5, 10 or 25 mg/day escalated the LDL-C amounts fol-
lowing 4 weeks of therapy along with atorvastatin supple-
mentation resulted in reduction of LDL-C amounts lower 
than baseline in each OCA group by 8th week [36]. OCA 
combination with atorvastatin was usually safe in addition 
to having a good tolerance.
This OCA use has further been expanded to cirrho-
sis, as well as a phase 3 trial of OCA in patients with 
compensated cirrhosis secondary to NASH is ongoing. 
Patients got randomly allotted to 1:1:1 to the groups 
receiving OCA 10 mg, 10 mg with titration to 25 mg 
OCA at 3 months, or placebo for 18 months (REVERSE, 
NCT03439254). In the REVERSE study utilization of 
dose enhancement strategy is done in view of hepatic 
decompensation resulting in patients where cholestatic 
liver disease is markedly advanced that gets therapy with 
OCA [37]. The primary end point is the percentage of cases 
showing benefit in fibrosis by a minimum of 1 stage with-
out any deterioration of NASH.
2.2 Non Bile Acid [FXR] Agonist
i) Tropifexor(LIN-452)
Tropifexor (TXR; LIN-452) represents a significant-
ly potent. Non bile acid FXR agonist, which stimulates 
the expression of target genes at minimal dosage with-
out any important Takeda G-protein coupled receptor 
clones 5 getting stimulated [38]. A phase 2 trial on TXR in 
NASH patients for 48 weeks is going on (FLIGHT-FXR, 
NCT02855164) [39]. During an interim evaluation of an 
ongoing trial for 12 weeks, akin to that of OCA, TXR il-
lustrated lipid alterations that were not favourable with a 
dose-associated escalation in the LDL-C amounts as well 
as a reduction in the high density lipoprotein cholesterol 
(HDL-C) amount, besides pruritus, at greater dosages in 
contrast to placebo. Further a relative reduction in the liv-
er fat amounts by magnetic resonance imaging (MRI) pro-
tein density fat fraction (MRI-PDFF) of -9.8% in placebo, 
-16.9% with TXR 60 mg , as well as -15.6% with TXR 90 
mg, in the interim evaluation. More evaluation illustrated 
that TXR possessed greater benefit in patients possessing 
a lesser body mass index (BMI), which pointed that a 
weight dependent strategy, might be essential [40].
ii) Cilofexor (GS-9674)
With OCA possessing troublesome adverse actions like 
pruritus, hyper cholesterolemia, in addition to hepatic de-
compensation, selective, non bile acid synthetic FXR ago-
nists have got generated. Cilofexor (GS-9674), represents 
a potent, nonsteroidal FXR agonist which basically works 
by stimulation of FXR in the intestine as well as don’t go 
through enterohepatic circulation [41]. FXR agonism in the 
intestine by Cilofexor amplifies the physiologic liberation 
of fibroblast growth factor (FGF) 19, as well as might 
ameliorate the harmful actions of the systemic FXR stim-
ulation, that are dyslipidemia. Pruritus hepatotoxicity [41]. 
10 subjects of NASH as well as fibrosis stage F2-F3 in a 
DOI: https://doi.org/10.30564/jer.v3i2.3580
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proof of concept study received 30 mg/day of Cilofexor 
for 12 weeks documented reduction of hepatic fat amounts 
as well as stiffness, along with enhancement of liver bio-
chemistry [42].
In a phase 2 trial 140 non cirrhotic as well as NASH 
patients got randomly allotted to Cilofexor 100 mg (n=56), 
Cilofexor 30 mg (n=56), or placebo (n=28) for 24 weeks 
(NCT02854605) [43]. The outcomes pointed that Cilofexor 
100 mg resulted in reduction in the hepatic fat amounts, 
along with had reasonable enough tolerance. Commonly 
Pruritus was not encountered, but had a greater frequency 
in 100 mg (14%) vis a vis 30 mg (4%) Cilofexor as well 
as placebo groups (4%). No variation in Pruritus was 
encountered at the Cilofexor 30 mg in contrast to place-
bo, however, like a lot of other FXR agonists, Cilofexor 
resulted in Pruritus in a dose based method, with greater 
moderate –severe Pruritus in the ones getting 100 mg dose 
in contrast to placebo. Cilofexor for 24 weeks led to a sig-
nificant decrease in hepatic steatosis, liver biochemistry, 
as well as serum bile acids in NASH patients. Other FXR 
agonists (nidufexor) [44], as well as EDP-305 [45] have got 
generated, being in phase 2 trials.
2.3 Fibroblast Growth Factor 19 (FGF19Analogue), 
NGM 282
The FGF family of hormones modulates metabolic 
functions in addition to tissue repair as well as regener-
ation [46]. FGF19 represents a downstream target of FXR 
getting activated, as well as FXR results in FGF19 liber-
ation via the intestine. FGF19 is a hormone that is con-
trolling bile acids generation along with glucose homeo-
stasis [47], whereas NGM 282 is an artificially generated 
FGF19Analogue (Figure 1).
During a phase 2 study having 82 patients that had bi-
 
Figure 1. Fibroblast Growth Factor 19 (FGF19Analogue), NGM 282
Courtesy ref no 31-Mechanism of action for nonalcoholic steatohepatitis treatment. OCA, obeticholic acid; HDL, high density 
lipoprotein; LDL, low density lipoprotein; SGLT2, sodium glucose cotransporter 2; FXR, farnesoid X receptor; THR-β, thyroid 
hormone receptor-β; LDL-R, low density lipoprotein receptor; SR-B1, scavenger receptor class B type 1; SREBP-2, sterol regulatory 
element-binding proteins-2; CYP7A1, cholesterol 7α-hydroxylase; SREBP-1c, sterol regulatory element binding protein-1c; ACC-
1, acetyl-coenzyme A carboxylase-1; FAS, fatty acid synthase; SCD1, stearoyl-CoA desaturase 1; PPAR, peroxisome proliferator-
activated receptor; LXRα, liver X receptor α; SHP, small heterodimer partner; ERK1/2, extracellular signal-regulated kinase 1/2; 
FGFR4, fibroblast growth factor receptor 4; FoxO1, forkhead box protein O1; CREB, cAMP response element-binding protein; FGF, 
fibroblast growth factor; FAO, fatty acid β-oxidation; CoA, coenzyme A; TCA, tricarboxylic acid; MPC, mitochondrial pyruvate 
carrier; TG, triglyceride; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6.
DOI: https://doi.org/10.30564/jer.v3i2.3580
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opsy validated NASH got randomly allotted to get 3 mg 
(n=27) or 6 mg subcutaneous NGM 282 (n=28) or pla-
cebo (n=27) (NCT02443116) [48]. The primary end point 
was the sheer alteration in liver fat amounts from baseline 
till week 12. Definition of responders were patients at-
taining a 5% or higher decrease in sheer liver fat amounts 
as estimated by MRI-PDFF. Subsequent to 12 weeks, 20 
(74%) patients in the 3 mg groups as well as 22 (79%) 
in the 6 mg groups attained a minimum of 5% decrease 
in sheer liver fat amounts from baseline vs 2 (7%) in the 
placebo groups. NGM 282 generated fast as well as sig-
nificant decrease in sheer liver fat amounts with the safety 
parameters that could be accepted in NASH patients. The 
histological efficiency of NGM 282 in a recent open label 
evaluation, in biopsy validated NASH was evaluated [49]. 
Paired liver biopsies from 43 patients delivered sub-
cutaneous NGM 282 (1 mg; n=24; 3 mg, n=19) once/
day for 12 weeks got assessed, that were blinded to time 
point, subject as well as clinical knowledge. At 12th week, 
NGM 282 enhanced the histological parameters of NASH, 
with important decreases in the NAS along with fibrosis 
scores, that was correlated with enhancement in noninva-
sive imaging in addition to serum markers. A larger phase 
2 study possessing a target of 250 enrolled biopsy vali-
dated NASH is presently enrolling in an active manner 
(NCT02443116).
2.4 Pegylated Fibroblast Growth Factor 21, 
Pegbelfermin (MBS-986036)
Fibroblast growth factor 21 (FGF21) has further been 
believed to be a part of bile acid pathway. Stimulation of 
FXR in addition to PPARα, results in hepatic expression 
as well as liberation of FGF21 [50]. FGF21, that represents 
a nonmitogenic hormone, that is a crucial controller of 
energy metabolism [52]. Endogenous FGF21 possesses a 
small half life of 1-2 h, but utilization of different manip-
ulation approaches have aided in generation of FGF21 
analogues that possess a longer half life. Pegbelfermin 
(MBS-986036), represent a polyethylene glycol that has 
been a conjugated recombinant analogue of Fibroblast 
growth factor 21 that possess a longer half life which aids 
in weekly dosing.
In a randomized, double blinded, placebo-controlled 
phase 2a trial, 75 patients having a minimum BMI of 25 
kg/m2, biopsy validated NASH (fibrosis stage 1-3) as well 
as liver fat amounts of a minimum of 10% by MRI-PDFF 
got randomized into 3 groups (25 patients to get 10 mg 
Pegbelfermin/day as well as in the groups getting 20 mg 
Pegbelfermin weekly in contrast to the placebo groups. 
Maximum side effects were mild, of which the com-
monest one was diarrhea in 8 (16%) of 49 patients who 
received Pegbelfermin. Pegbelfermin treatment for 16 
weeks was usually well accepted as well as significantly 
led to a reduction in hepatic fat fraction in patients with 
NASH. At present 2 large trials in phase 2 (FALCON 1, 
n=160, FALCON 2, n=152) are ongoing for evaluation of 
the effectiveness in addition to safety of Pegbelfermin.
2.5 Insulin Resistance
i) Peroxisome Proliferator Activated Receptor 
(PPAR )-agonist
a) Elafibranor
PPARs represent nuclear Receptors that possess critical 
part in cellular events controlling metabolic homeostasis. 
Three kinds of nuclear Receptors isoform, PPARα PPARβ/
δ as well as PPARγ, that get encoded by separate genes [54]. 
Elafibranor (GFT505) is a double PPARα as well as δ ago-
nist, which controls the lipid along with insulin metabolism. 
Maximum PPARα expression occurs in the liver, whose 
activation is performed by hypolipidemic fibrates. PPARα 
has the role of regulation of the lipid flux in the liver via 
modulation of fatty acids (FA) as well as β oxidation along 
with results in enhancement of plasma lipids by reduction 
in the triglycerides amounts as well as causing escalation 
of HDL-C [55]. In reference to advanced NASH, the PPARα 
amounts are decreased, that return to normal subsequent to 
treatment as well as enhancement [56]. PPARδ (alias PPARβ) 
controls the metabolism in the liver as well as peripheral 
tissues. PPARδ agonists cause enhancement of FAtransfer 
in addition to oxidation, escalated the HDL-C amounts, as 
well as enhance glucose homeostasis as well as escalation of 
insulin sensitivity as well as hampering hepatic glucose out-
put [57]. In a pilot trial, a selective PPARδ agonist, decreased 
hepatic fat amounts, as well as led to enhancement of insulin 
sensitivity along with plasma lipid amounts in addition to 
reduction in the γGT amounts [58].
From the phase 2b study, performed on Elafibranor 
patients presenting with NASH who were non cirrhotic 
got randomized into getting Elafibranor 80 mg (n=83), 
elafibranor 120 mg (n=91) or placebo groups (n=92)/day 
for 52 weeks (GOLDEN 505, (NCT01694849) [25]. The 
primary end point was NASH getting resolved without 
deterioration of fibrosis, with the utilization of protocol 
definition as well as modification of definitions. During 
an intention to treat evaluation, no important variations 
among the Elafibranor as well as placebo groups in the 
primary end point was observed. Nevertheless, in a 
posthoc evaluation of patients with NAS (≥4) (n=234), 
elafibranor 120 mg demonstrated resolution of NASH 
in a larger percentage of patients in contrast to placebo, 
DOI: https://doi.org/10.30564/jer.v3i2.3580
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dependent on the definition of protocol (20% vs 11%; 
odds ratio 3.16, 3.52; p=0.013). Further patients where 
elafibranor resulted in resolution of NASH. Subsequentl 
to receipt of Elafibranor 120 mg demonstrated reduction 
in liver fibrosis in contrast to those where no resolution of 
NASH resulted. The amounts of liver enzymes, lipids as 
well as systemic inflammation in addition to glucose pro-
file illustrated significant reduction in the elafibranor 120 
mg vis a vis placebo groups. Tolerance of Elafibranor was 
good without resulting in weight accretion or cardiac pro-
cesses, although did lead to mild reversible enhancement 
of the serum creatinine amounts.
A phase 3 trial one Elafibranor comprising of 2000 
NASH patients (NAS(≥4) with stage 2-3 fibrosis is on-
going (RESOLVE-IT, NCT02704403). The primary end 
points is the percentage of patients where resolution of 
NASH without deterioration of fibrosis resulted at 72 
weeks. Further the trial did an analysis of a composite 
long term results, comprising all cause mortality, cirrhosis 
as well as liver associated results at 4 years. The trial got 
initiated in March 16 as well as the outcomes are expected 
in December 21.
b) Lanfibranor
Lanfibranor (IVA337) represents an agonist of all the 3 
isoforms of, having a well balanced stimulation of PPARα 
as well as δ, along with part stimulation of PPARγ [59]. 
Whereas other PPAR agonists target 1 or 2 of the PPAR 
isoforms. Lanfibranor represents the lone pan PPAR ago-
nists that is undergoing clinical generation.
In a phase 2b clinical trial conducted on lanfibranor 
(IVA337) in case of patients with NASH in addition to 
liver steatosis as well as moderate to robust necroinflam-
mation without cirrhosis, 247 patients got randomized 
into getting Lanfibranor 800 mg, 1200 mg or placebo/day 
for 24 weeks (NATIVE, NCT03008070). The primary end 
point was a reduction from baseline in the SAF (steatosis, 
activity as well as fibrosis) activity score. The study got 
initiated in January 2017 as well as was over by March 
2020. The early outcomes were anticipated in December 
2020 first half.
ii) a.Glucagon like peptide 1(GLP-1) Receptor 
agonist-Semaglutide 
No Pharmacological treatments have got proven for 
NASH in addition to T2DM. The major thing is to find 
the most appropriate anti diabetic agents for the therapy 
of NASH, for avoidance of the propagation of hepat-
ic fibrosis as well as cardiovascular or renal processes. 
Glucagon like peptide 1 (GLP-1) Receptor agonist along 
with Sodium–glucose cotransporter 2 (SGLT2) inhibitors 
are anticipated to mitigate NASH in addition to NAFLD. 
GLP-1 represents a gut generated incretin hormone which 
stimulates reduction of weight of patients along with 
insulin sensitivity. GLP-1 analogues got approval for uti-
lization in T2DM along with obesity. The advantages of 
these analogues are weight reduction, escalated glycaemic 
regulation, lesser hypoglycemia processes along with a 
decreased incidence of cardiovascular processes [60,61]. The 
part of GLP-1 in the management of NASH along with 
NAFLD appear lucrative [17,62,63].
In a recent randomized, placebo-controlled trial impli-
cating 52 patients with biopsy corroborated NASH 1.8 mg 
of subcutaneous Liraglutide delivered/day for 48 weeks 
had a correlation with greater NASH resolution as well as 
lower propagation of fibrosis [17]. Nevertheless, the Amer-
ican Association for the study of liver disease practice 
guidance 2018 advocated that it was preterm to think of 
GLP-1 agonists for the treatment of liver disease in cases 
of NASH along with NAFLD [23].
Semaglutide represents a novel GLP-1 analogue that 
posseses a prolonged half life of about a week. During 
phase 2 study of the actions of Semaglutide on NASH, 
320 patients with NASH got randomly allocated to pla-
cebo groups or 3 dosage amounts of Semaglutide by sub-
cutaneous injection for 72 weeks (NCT02970942). The 
primary end point comprised resolution of NASH without 
deterioration of fibrosis. Early outcomes from the study 
were anticipated in May 2020. In a separate phase 2 study 
implicating weekly Semaglutide 2.4 mg x 48 weeks. The 
primary results are enhancement of amelioration of liver 
fibrosis by a minimum of a stage without deterioration of 
NASH following 48 weeks (NCT0387451). Semaglutide 
seems to be the one that is most attractive for the treat-
ment of NASH correlated with DM. Nevertheless, if GLP-
1 analogues escalated hepatic inflammation resolution or 
fibrosis in NASH is not clear as yet.
b) Dapagliflozin, a Sodium –glucose cotransporter 
2 inhibitor
Sodium–glucose cotransporter 2 (SGLT2) inhibitors ham-
per glucose reabsorprtion in the proximal tubule, resulting in 
glucosuria, resulting in decrease of plasma glucose amounts. 
Hence, (SGLT2) inhibitors possess a treatment potential for 
both NASH along with NAFLD. Certain studies (small) have 
demonstrated the action of Dapagliflozin in case of patients 
with NAFLD as well as type2 Diabetes mellitus (T2DM) [64]. 
Despite the probability can’t be ruled out that a fall in body 
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weight or visceral adipose tissue (VAT) secondary to Dapag-
liflozin might be correlated with a reduction in hepatic ste-
atosis or fibrosis, Dapagliflozin demonstrated an advantage 
in patients with NAFLD. A multicenter, randomized, place-
bo-controlled phase 3 Clinical trial is ongoing for evaluation 
of the effectiveness as well as safety of Dapagliflozin for the 
therapy of NASH (DEAN, NCT03723252). The primary 
end point is enhancement of the liver histological score at 12 
month. 100 subjects with NASH got randomly allocated to 
placebo groups or10 mg of Dapagliflozin. This study got in-
itiated in March 19, as well as outcomes awaited in Novem-
ber 21.
2.6 Mitochondrial Target of Thiazolidenedione- 
MSDC-0602K
1st generation insulin sensitizers thiazolidenediones have 
the ability to directly bind to as well as stimulate the PPARγ 
nuclear hormone Receptors as well as have got utilized for 
the treatment of T2DM [65]. Nevertheless, they are correlated 
with important adverse actions like edema, bone fractures 
that get modulated by PPARγ, along with hypoglycemia. The 
2nd generation insulin sensitizer MSDC-0602K got fashioned 
for decreasing these adverse actions, whereas continuing to 
generate insulin sensitizing Pharmacology in case of animal 
models of DM [66], as well as NASH [67]. It manipulates the 
action of extra nutrition at mitochondrial pyruvate carrier 
(MPC) with least PPARγ binding (Figure 1) [68]. Earlier stud-
ies demonstrated, that MSDC-0602K had the capacity of 
enhancement of lipid oxidation, as well as diminish denovo 
lipid generation as well as gluconeogenesis in the liver, both 
in vivo, as well as in vitro, without adverse actions of the 1st 
generation insulin sensitizers [69].
During a randomized, double blinded, placebo-con-
trolled phase 2b trial for 52 weeks patients with biopsy 
corroborated NASH as well as fibrosis (F1-F3) got a 
random allocation to placebo groups (n=94) or 62.5 
mg (n=99), 125 mg, (n=98) or 250 mg (n=101) of MS-
DC-0602K (EMMINENCE, NCT02784444) [70]. The 
primary end point for effectiveness was the hepatic histo-
logical enhancement of ≥2 points in NAS with a ≥1point 
decrease in ballooning or lobular inflammation as well as 
no escalation in fibrosis stage at 12 months time duration. 
No significant influence on liver histology was observed 
in that particular study secondary to MSDC-0602K. Nev-
ertheless, significant reduction in amounts of fasting blood 
glucose, insulin, glycated haemoglobin, as well as mark-
ers of liver damage without any dose restricting adverse 
actions. A phase 3 study was supposed to get started in 
2020 (MMONARCh, NCT03970031).
2.7 Inflammation
i) C-C chemokine receptor CCR Dual types 2 as 
well as 5(CCR2/CCR5) antagonist (cenicriviroc)
CVC or cenicriviroc represents an oral double antago-
nist of CCR2 as well as CCR5. Once CCR2 gets blocked 
that represents a chemokine receptor that mainly gets 
expressed in monocyte, along with, macrophages, causes 
a reduction in monocyte, along with macrophages, their 
migration in addition to infiltration of these cells towards 
the damaged areas of the liver [71]. Simultaneous inhibition 
of CCR5 interferes with the migration, activation along 
with proliferation of the activated hepatic stellate cells [71].
During a phase 2b trial for CVC in case of patients with 
NASH (NAS≥4) with fibrosis (F1-F3), 289 patients got a 
random allocation to either CVC 150 mg or placebo groups. 
The primary end point decided was a ≥2 point enhancement 
in NAS in addition to no deterioration of fibrosis at 1 year 
(CENTAUR, NCT02217475) [26,72]. The primary end point 
of enhancement in NAS in the intention for treatment pop-
ulation as well as NASH resolution was attained in an akin 
percentage of cases on CVC (n=145) as well as placebo. 
Nevertheless, the fibrosis end point was achieved in greater 
amounts of cases on CVC in contrast to placebo (20% vs 
10%, p=0.02). Therapeutic advantages were higher in those 
displaying greater disease activity in addition to fibrosis stage 
at baseline. Subsequent to 1 year of CVC therapy double the 
number of patients attained in fibrosis without deterioration 
of NASH in contrast to placebo.
AURORA (NCT03028740), a randomized, double 
blinded, placebo-controlled, multicenter, phase 3 trial is 
ongoing for evaluation of efficacy as well as safety of 
CVC therapy for liver fibrosis in 2000 subjects of NASH 
presenting with stage 2-3 fibrosis. This study is planned 
in 2 parts. Part 1 is meant for evaluation of the surrogate 
end point of enhancement in fibrosis with a minimum of 
one stage as well as without deterioration of NASH at 12 
months. Those cases from part 1 would resume in part 2 
in addition to further extra patients added would get re – 
randomized in part 2 for estimating the long duration clin-
ical results - histopathological – propagation to cirrhosis, 
Liver-associated Clinical features, in addition to all cause 
Mortality. This trial got initiated in April 2017, with the 
outcomes anticipated in December 2024.
2.8 Thyroid Hormone Receptor β-agonist (THR-β- 
agonist)
Resmetriom (MGL-3196)
The Thyroid hormone Receptor (THR-β) gets signifi-
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cantly expressed in the hepatocyte. NASH may represent 
partially, a problem secondary to reduction of liver thyroid 
hormone amounts or hepatic hypothyroidism, along with 
the incidence of clinical as well as sub clinical hypothy-
roidism is greater in subjects with NAFLD or NASH in 
contrast to those age matched controls [73,74]. Activation 
of THR-β causes the advantageous metabolic actions on 
triglycerides as well as cholesterol amounts in addition 
to enhancement of hepatic steatosis [73]. Possessing the 
actions of beneficial cardiometabolic profile along with 
ameliorated hepatic steatosis, THR-β- agonist are getting 
evaluated for NASH therapy.
Resmetriom (MGL-3196) acts as a liver pointed, orally 
working selective THR-β- agonist fashioned to provide 
relief in NASH by escalation of hepatic fat metabolism as 
well as reduction in lipotoxicity. During a phase 2 study, 
patients having biopsy verified NASH (fibrosis stage 1-3) 
as well as hepatic fat percentage ≥10% by MRI-PDDF got 
a random allocation to 2:1 for getting Resmetriom 80 mg 
or matching placebo, orally once/day (NCT02912260) [27].
The primary results were the proportional alterations 
from baseline in hepatic fat percentage as evaluation done 
by MRI-PDDF at 12 weeks.A significant decrease in he-
patic fat percentage following 12 as well as 36 weeks of 
Resmetriom was observed. Tolerance was good, neverthe-
less, it resulted in Gastrointestinal tract (GIT), side effects, 
that were self restricted as well as were not responsible for 
the study getting withdrawn.
A Phase 3 trial implicating 2000 patients with NASH 
along with stage 2.3 fibrosis is ongoing (MAESTRO-NASH, 
NCT03900429). The primary result is the action of Resme-
triom 80 or 100 mg in contrast to placebo on liver histol-
ogy along with a composite long duration results of the 
amount of patients with the initiation of any of the consid-
ered processes like cirrhosis, all cause mortality, as well 
as liver associated Clinical features. This trial got initiated 
in March 2019, with the outcomes anticipated in March 
2024.
VK2809
VK2809 represents a small molecule product of a ro-
bust THR-β-agonist. VK2809 gets selectively cleaved in 
the Liver tissue by the enzyme cytochrome P450 isozyme 
3A4, to liberate a pharmacologically active metabolite. 
During a Phase 2a trial, patients possessing a hepatic fat 
amounts of ≥8% as evaluation done by MRI-PDDF, a 
LDL-C amount of ≥110 mg/dl, along with a triglycerides 
amount of ≥120 mg/dl got a random allocation to get oral 
VK2809 5 mg/day, 10 mg alternate day, 10 mg/day or pla-
cebo for 12 weeks [75].
Significant drop in hepatic fat amounts by MRI-PDFF 
in contrast to placebo was documented in the patients get-
ting VK2809. The median relative alteration from baseline 
in hepatic fat amounts was 53.8% for VK2809 5 mg/day 
(p=0.0001). 56.1% for 10 mg alternate day (p=0.0018) as 
well as 59.7 for 10 mg/day (p=0.0004) vs 9.4% for place-
bo.
Dependent on these outcomes, a Phase 2b study is 
ongoing in 337 subjects with biopsy validated NASH, 
for evaluation of the effectiveness along with safety of 
VK2809 (1.0,2.5,5.0,10 mg) vis a vis placebo for 52 
weeks. The primary result is the relative alteration in he-
patic fat amounts (evaluation by MRI-PDFF) from base-
line to12 weeks (VOYAGE, NCT04173065). The study 
was initiated in November 2019.
2.9 Hepatic Lipid Metabolism
i) Stearoyl-Co A Desaturase (SCD1) Inhibitor- 
Aramchol
Aramchol represents arachidylamido cholanoic acid, that 
is an innovative synthetic lipid molecule, a conjugate of the 
bile acid, cholic acid as well as arachidic acid, a fatty acid. It 
results in transformation of saturated FAsinto monounsatu-
rated FAs (Figure 1) [76]. Aramchol has been evaluated in a 
Phase 2a trial, over 3 months at doses of 100 mg as well as 
300 mg/day. This study illustrated a decrease in hepatic fat by 
magnetic resonance spectroscopy (MRS) following 3 months 
of treatment in the 300 mg/day Aramchol group in contrast 
to placebo, but not in the 100 mg/day Aramchol group. Fur-
ther a decrease in the ALT amounts, with the compounds 
being well tolerated [77]. Greater doses of Aramchol (400 
mg/day-600 mg/day) were delivered to patients with biopsy 
validatedNASH (n=247) without cirrhosis in a Phase 2b trial 
which analysed their actions on liver triglycerides amounts 
with the utilization of (MRS) as well as liver biopsy (AR-
REST-NCT02279524) [28]. A significant ≥5% decrease in he-
patic fat amounts was seen with 600 mg/day Aramchol, 47% 
in contrast to placebo, 24%. As per liver histology, NASH 
resolution without deterioration of fibrosis was observed in 
greater instances with 600 mg Aramchol in contrast to place-
bo (16.7% vs 5% OR, 4.74; 95% CI, 0.99-22.66). Despite the 
study being underpowered for histological evaluation a dose 
response pattern in favour of NASH resolution as well as 
fibrosis amelioration was observed. A Phase 3/4 multi nation-
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al, multicenter, double blinded, placebo-controlled study for 
analyzing the effectiveness along with safety of Aramchol in 
cases with NASH (fibrosis 2 or 3) who present as overweight 
or with obesity along with prediabetes or T2DM (ARMOR, 
NCT04104321) has been continuing since September 2019.
ii) LiverX Receptor-α inhibitor- Oltipraz
Oltipraz represents a synthetic dithiolethione which 
works as anti steatotic drug by hampering LiverX Recep-
tor-α (LXR –α) activity (Figure 1) [78]. Dithiolethiones are 
an innovative class of adenine monophosphate activated 
protein kinase (AMPK) stimulators, that avoid insulin 
resistance (IR) by hampering AMPK-based p70ribosomal 
S6 kinase1 (S6K1). AMPK represents a serine/threonine 
kinase possessing a key part in the controlling of car-
bohydrates as well as fat metabolism, besides which it 
might result in modulation of LXR–α action along with 
causing a reduction in expression of sterol regulatory ele-
ment binding protein 1c (SREBP1c), a crucial Controller 
of lipid generation [79]. Oltipraz has a treatment potential 
for steatosis by stimulation of AMPK in addition to ham-
pering S6K1. Further it encourages lipid oxidation by 
hampering LXR–α action along with resulting in reduc-
tion in expression of SREBP1c in the liver [78]. A Phase 
2 study is presently continuing in patients with hepatic 
fat amounts>20% as well as hypertransaminasaemia got 
random allocation to get placebo (n=22), 30 mg Oltipraz 
(n=22), 60 mg Oltipraz (n=24), bdx 24 weeks (PMK-
N01GH, NCT01373554) [80]. The primary result was the 
alteration in the hepatic fat amounts as evaluated by MRS 
from baseline x 24 weeks.
In contrast to placebo groups, a significant reduction in 
the hepatic fat amounts was caused by Oltipraz in a dose–
based manner. Nevertheless, the sheer alterations in IR 
along with the amounts of liver enzymes, lipids as well 
as cytokines were not significantly altered in any of the 
groups. Moreover the side effects were similar among the 
groups.
A multicenter, randomized, double blinded, place-
bo-controlled parallel, phase 3 Clinical trial is going on 
for analyzing the effectiveness along with safety of Olti-
praz in 144 subjects with NAFLD (NCT04142749). The 
primary results is the difference in the amounts of liver fat 
as evaluated by MRS at 24 weeks in contrast to baseline. 
The study was initiated in December 2019, with early out-
comes anticipated in October 21.
iii) Acetyl-CoA Carboxylase inhibitor, firsocostat 
(GS0976)
The Controlling of denovo lipogenesis (DNL) possess-
es a main part in the fatty acids (FA) generation along 
with their catabolism. The rate restricting step in DNL is 
transformation of Acetyl-Coenzyme A (Acetyl-CoA) to 
malonyl CoA by the enzyme Acetyl-CoA Carboxylase 
(ACC). ACC possesses 2 isoforms. The ACC 1isoform 
catalyzes the generation of malonyl CoA, that is the main 
substrate for the (FA) generation within the cytosol. ACC2 
resides in the mitochondria, where malonyl CoA works as 
a robust allosteric inhibitor of carnitine palmitoyl trans-
ferase (CPT)1, that is the carrier protein of FA into mito-
chondria for the β oxidation [77,81]. Hampering of ACC 1 as 
well as ACC 2 would get anticipated to decrease DNL as 
well as a escalate mitochondria β oxidation, respectively, 
pointed that hampering of ACC would be a treatment tar-
get in NASH [82]. Firsocostat (GS0976) represents a liver 
targeted, small molecule allosteric inhibitor of both ACC 
1 as well as ACC 2 in the generation of NASH (Figure 1).
During a recent phase 2 trial, 126 cases with hepatic 
steatosis of ≥8% dependent on MRI-PDFF, as well as liver 
stiffness of ≥2.5 kPa, dependent on MRE, or biopsy that 
corroborated with NASH as well as F1-F3 fibrosis got a 
random allocation to (2:2:1) for getting GS0976 (20 mg), 
GS0976 (5 mg), or placebo groups day for 12 weeks. Dur-
ing that study, 20 mg delivery of GS0976 was safe along 
with resulted in significant decrease in liver fat amounts 
by MRI-PDFF as well as a reduction in TIMP1. That is a 
marker of fibrogenesis (NCT02856555) [83].
2.10 Anti Fibrotic Drugs
i) Galectin-3 inhibitor, Belamectin (GRMD-02)
Galectins represent carbohydrate-binding proteins that 
belong to the family of non-integrinβ-galactoside–binding 
lectins [84]. Galectin-3 (Gal-3) is the commonest Galec-
tin liberated in disease, basically by macrophages. Gal-
3 through its intracellular (antiapoptotic, macrophages 
differentiation) along with extracellular (chemokinetic 
as well as chemotactic factor) actions is significant to the 
pathophysiology of hepatic fibrosis that result secondary 
to a lot of chronic Liver diseases [85,86]. Galectin inhibitors 
represent a new class of drugs which target both liberated 
as well as membrane – correlated Galectins in view of 
their high molecular weight [87]. Belamectin (GRMD-02), 
represents galactoarabino-rhamnogalacturonate) is a com-
plicated carbohydrate molecule obtained from anatural 
plant source, that possesses oligosaccharide chains having 
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galactose residues as well as binds to the Galectin3 with a 
lesser amount to Galectin1. A phase 1 study has illustrated 
that Belamectin possesses good effectiveness along with 
safety at single along with multiple doses of 2, 4 as well 
as 8 mg/kgin patients possessing NASH having all proper-
ties of proved NASH in addition to advanced fibrosis but 
no cirrhosis [88].
During a multicenter, randomized double blinded, pla-
cebo-controlled phase 2b trial, 162 patients with NASH, 
cirrhosis as well as portal hypertension (with hepatic ve-
nous pressure gradient [HVPG]≥6 mmHg) got a random 
allocation to get biweekly infusion of Belamectin 2 mg/kg 
(n=54), 8 mg/kg (n=54), or placebo (n=54) for 52 week 
[89]. The primary end point was the alteration in HVPG 
(-28) by the finishing of 52 weeks duration in contrast to 
baseline. Despite belpectin being safe, it was not corre-
lated with a significant decrease in HVPG or fibrosis, in 
contrast to placebo. Nevertheless in a subgroup evaluation 
of patients without esophageal varices, 2 mg/kg belapec-
tin actually led to a reduction in the generation of varices. 
A phase 3 study for analyzing the safety along with ef-
fectiveness of belapectin for the avoidance of esophageal 
varices in case of as well as patients with NASH cirrho-
sis without esophageal varices is getting started (NCT 
04365868).
3. Combination Treatment
NASH represents a multifactorial disease implicating 
various modes for its genesis with no definite approved 
treatments. In future combination of drugs are attractive 
in view of targeting a lot of pathways. Maximum drug 
combinations are constituted by metabolic, inflammatory 
as well as fibrotic drugs or as an other way an anti diabet-
ic might be utilized. At present 3 Combination treatments 
options for NASH are there. 
3.1 TXR as well as CVC 
A randomized, double blinded, multicenter, place-
bo-controlled phase 2b study for patients evaluation of 
safety along with effectiveness of TXR as well as CVC 
IN 200 cases with NASH fibrosis (stage2/3) (TANDEM, 
NCT03517540) [90]. Randomization of patients in a 1:1:1:1 
ratio for getting TXR 140 µg+CVC 150 mg once a day. 
The study is designed as a 48 week treatments time as 
well as 4 week follow up. The primary aim is analysis of 
safety along with tolerance of this combination treatments 
as compared to monotherapies over 48 weeks. The sec-
ondary aim is effectiveness that by definition is ≥1 point 
enhancement in liver fibrosis vis a vis baseline or resolv-
ing of steatohepatitis following 48 weeks. Thus this com-
bination treatments targets steatotic, inflammatory as well 
as /or fibrotic pathways that are accountable for NASH.
3.2 Selonosertib, Firsocostat, as well as Cilofexor 
A recent phase 2 study analysed safety along with ef-
fectiveness of a combination of Selonosertib, firsocostat, 
as well as cilofexor in patients with bridging fibrosis of 
compensated cirrhosis without deterioration of NASH. 
Results were anticipated in 2020.
3.3 Semaglutide, Firsocostat as well as Cilofexor
During a phase 2 study where utilization of combina-
tion of Semaglutide, firsocostat as well as cilofexor was-
done, 109 cases presenting with NASH fibrosis (stage 2/3) 
got a random allocation to Semaglutide groups, Sema-
glutide+ firsocostatgroup, Semaglutide+ cilofexor 30 mg 
group, Semaglutide+ cilofexor 100 mg, or Semaglutide + 
firsocostat + cilofexor group (NCT039U7074). The pri-
mary aim is analysis of safety along with tolerance of the 
study drug/drugs in adult cases with NASH.
3.4 TXR as well as Licogliflozin
Licogliflozin is a once/day, oral SGLT1/2 double in-
hibitor. A phase 2b randomized, double blinded, multi-
center, study is doing evaluation of the safety along with 
effectiveness of as well as tolerance of oral TXR as well 
as licogliflozin in combination treatments in contrast to 
monotherapies, in case of subjects with NASH as well 
as liver fibrosis. The primary end point is the population 
of patients with NASH resolution by a minimum of one 
stage without deterioration of fibrosis at 48 weeks in con-
trast to baseline (ELIVATE, NCT 04065841).
4. Conclusions
Despite Vitamin E, pioglitazone, Liraglutide cause 
enhancement of liver histology, no FDA approved agent 
exist for NASH currently. Hence weight reduction by 
utilization of lifestyle modifications, that are diet along with 
exercise remains the major way of treatment of NAFLD. 
Here we have given an overview of the key phase 2-3 trials 
dependent on the mode of working in NASH (Figure 2).
5 Pharmacological drugs like Obeticholic acid, elafi-
branor, cenicriviroc, resmetriom, in addition to aramchol 
are getting analysed in big, histology dependent phase 3 
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trials. Depending on the outcome of these trials, newer 
agents possessing greater efficacy are anticipated in 2 to 
4 years. Various phase 2 trials are ongoing with different 
drugs like non bile acid Farsenoid X receptor antagonists, 
FGF19 along with 21 analogues, GLP-1RA, SGLT2 in-
hibitors, pan-PPAR agonists, MPC inhibitors. ACC inhib-
itors as well as Gal-3 antagonists. Combination treatments 
are further getting analyzed. In view of NASH occurring 
secondary to a lot of factors combination treatments ap-
pear to be promising. Lastly, finally further approaches of 
treatments would be composed of combination treatments 
along with precision medicine depending on the various 
phenotypes of NASH along with personalised patients 
treatment response. 
 
Figure 2. key phase 2-3 trials dependent on the mode of working in NASH
Courtesy ref no 31-The classification of phase 2,3 trials based on mechanism of action in nonalcoholic steatohepatitis (NASH) 
treatment. FXR, farnesoid X receptor; FGF, fibroblast growth factor; PPAR, peroxisome proliferator-activated receptor; SGLT2, 
sodium glucose cotransporter 2; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MPC, mitochondrial pyruvate carrier; SCD1, 
stearoylCoA desaturase 1; ACC, acetyl-coenzyme A carboxylase; THR-β, thyroid hormone receptor-β.
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